New IV drug for MRSA/VRE

Telavancin has been FDA approved for treatment of complicated skin/soft tissue infections due to multi-drug resistant gram positive organisms. It is an IV lipoglycopeptide with Qday dosing and no need for drug level monitoring. It was proven non-inferior to vancomycin in two phase 3 trials (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment